<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096330</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000393455</org_study_id>
    <secondary_id>P30CA016056</secondary_id>
    <secondary_id>RUH-PHO-0514-0404</secondary_id>
    <secondary_id>RPCI-EPR-20703</secondary_id>
    <secondary_id>AECM-0401022E</secondary_id>
    <secondary_id>NEMCH-6060</secondary_id>
    <nct_id>NCT00096330</nct_id>
  </id_info>
  <brief_title>Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer</brief_title>
  <official_title>Phase I Clinical Study of Folate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain agents to try to prevent the&#xD;
      development of cancer. The use of folic acid may be effective in preventing colorectal&#xD;
      cancer. Eating a diet rich in folic acid may prevent the development of colorectal cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase I trial is studying how well a folate-depleted diet works&#xD;
      compared to a folate-supplemented diet in preventing colorectal cancer in patients who are at&#xD;
      high risk for developing colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related&#xD;
           DNA endpoints (e.g., genomic and gene-specific DNA methylation and DNA strand breaks) in&#xD;
           rectal epithelial cells in patients at high risk for colorectal neoplasia.&#xD;
&#xD;
        -  Analyze the effects of these dietary interventions on folate-related DNA endpoints&#xD;
           (e.g., genomic and gene-specific DNA methylation, DNA strand breaks, and uracil&#xD;
           incorporation into DNA) in blood mononuclear cells in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Analyze the effects of these dietary interventions on the patterns of differential gene&#xD;
           expression in rectal epithelial cells and blood mononuclear cells in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, single-blind study.&#xD;
&#xD;
        -  Run-in period: Patients are placed on an average folate-containing diet for 56 days.&#xD;
&#xD;
        -  Randomization: After completion of the run-in period, patients are randomized to 1 of 2&#xD;
           arms.&#xD;
&#xD;
             -  Arm I (folate depleted diet): Patients are placed on a low-folate diet for 84 days.&#xD;
                Patients receive oral folic acid supplementation once daily on days 57-84.&#xD;
&#xD;
             -  Arm II (folate supplemented diet): Patients continue on an average&#xD;
                folate-containing diet for an additional 56 days. Patients receive oral folic acid&#xD;
                supplementation once daily on days 1-56.&#xD;
&#xD;
      Patients are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients (10 per arm) will be accrued for this study within&#xD;
      2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>•Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints</measure>
    <time_frame>pre and post treatment</time_frame>
  </primary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dietary intervention</intervention_name>
    <description>oral folic acid supplementation once daily on days 57-84</description>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>folic acid</intervention_name>
    <description>oral folic acid supplementation once daily on days 1-56.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Healthy persons at increased risk for colorectal neoplasia due to 1 of the following&#xD;
             reasons:&#xD;
&#xD;
               -  Personal history of colorectal adenomatous polyps&#xD;
&#xD;
               -  Family history of colorectal adenoma or adenocarcinoma&#xD;
&#xD;
          -  No history of multiple family members with colorectal neoplasia that is suggestive of&#xD;
             dominant hereditary neoplasia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  40 to 72&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Ambulatory&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  No excessive bleeding or coagulation disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT or AST ≤ 2 times upper limit of normal&#xD;
&#xD;
          -  No unexplained elevated alkaline phosphatase&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Homocysteine concentration ≤ 17um/L&#xD;
&#xD;
          -  No sustained blood pressure &gt; 150/95 mm Hg for 3 consecutive readings&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Vitamin B_12 ≥ 250 pg/mL&#xD;
&#xD;
          -  Folate level ≤ 20 mg/dL&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 weeks after study&#xD;
             participation&#xD;
&#xD;
          -  No intestinal malabsorption or inflammatory bowel disease&#xD;
&#xD;
          -  No prior malignancy except nonmelanoma skin cancer&#xD;
&#xD;
          -  No calcium metabolism abnormalities or predisposing conditions, such as&#xD;
             hyperparathyroidism&#xD;
&#xD;
          -  No untreated hyperthyroidism&#xD;
&#xD;
          -  No untreated insulin-requiring diabetes mellitus&#xD;
&#xD;
          -  No daily alcohol intake &gt; 2 ½ shot glasses of whiskey or three 8 ounce glasses of beer&#xD;
             or wine&#xD;
&#xD;
          -  No other serious illness that might limit life expectancy to &lt; 6 months&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  None&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  None&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormone replacement therapy, including oral, transplanted, or injected&#xD;
             contraceptives&#xD;
&#xD;
          -  Concurrent thyroid hormone replacement is allowed as long as the patient is euthyroid&#xD;
             for 3 months&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  None&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior gastrointestinal surgery, including gastrectomy or small or large bowel&#xD;
             resections&#xD;
&#xD;
               -  Prior appendectomy or surgery of the esophagus allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 months since regular ingestion of ≥ 650 mg per day of aspirin (≥ 2 tablets&#xD;
             of 325 mg regular strength OR &gt; 1 tablet of 500 mg extra strength aspirin)&#xD;
&#xD;
          -  More than 3 months since regular daily ingestion of nonsteroidal anti-inflammatory&#xD;
             drugs&#xD;
&#xD;
          -  At least 1 month since vitamin, mineral, or herbal supplementation&#xD;
&#xD;
          -  No other concurrent vitamin, mineral, or herbal supplementation&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
&#xD;
          -  No concurrent sterol-binding resins (i.e., cholestyramine)&#xD;
&#xD;
          -  No other concurrent investigational drugs or medications that might alter rectal&#xD;
             mucosal proliferation, folate metabolism, or renal/hepatic impairment&#xD;
&#xD;
          -  No concurrent weight control medications&#xD;
&#xD;
          -  No concurrent supplemental folate preparations containing &gt; 400 mcg of folic acid per&#xD;
             day&#xD;
&#xD;
          -  No concurrent lipid-lowering medications&#xD;
&#xD;
               -  The following concurrent statin drugs are allowed provided patient has been&#xD;
                  taking a stable dose for ≥ 1 month:&#xD;
&#xD;
                    -  Atorvastatin 10 or 20 mg/day&#xD;
&#xD;
                    -  Fluvastatin 20 or 40 mg/day&#xD;
&#xD;
                    -  Lovastatin 10 or 20 mg/day&#xD;
&#xD;
                    -  Pravastatin 10 or 20 mg/day&#xD;
&#xD;
                    -  Simvastatin 5 or 10 mg/day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Marshall, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

